Rifamycin in Minimal Hepatic Encephalopathy (RIVET)
A Double-Blind Randomized Placebo-Controlled Trial of Rifamycin SV MXX in Minimal Hepatic Encephalopathy (RIVET Trial)
Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center
Listed as NCT04082780, this PHASE2 trial focuses on Cirrhosis, Liver and Hepatic Encephalopathy and remains completed. Sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center, it has been updated 12 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Oct 2023 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Mar 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Feb 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2019 — Mar 2020 [monthly]
Recruiting PHASE2
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hunter Holmes Mcguire Veteran Affairs Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .